Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers

TitleEffects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers
Publication TypeJournal Article
Year of Publication2011
AuthorsKudoh, K, Takano, M, Kouta, H, Kikuchi, R, Kita, T, Miyamoto, M, Watanabe, A, Kato, M, Goto, T, Kikuchi, Y
JournalGynecol Oncol
KeywordsAdult Aged Antibodies, Humanized Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use Disease-Free Survival Doxorubicin/administration & dosage/adverse effects/*analogs & derivatives/therapeutic use Female Humans Lymphatic Metastasis Middle Aged Neop, Local/*drug therapy/mortality Ovarian Neoplasms/*drug therapy/mortality Polyethylene Glycols/administration & dosage/adverse effects/*therapeutic use, Monoclonal, Monoclonal/administration & dosage/adverse effects/*therapeutic use Antibodies

OBJECTIVES: Currently, pegylated liposomal doxorubicin (PLD) is regarded as one of the standard treatment options in recurrent ovarian cancers (ROC). Bevacizumab has shown significant antitumor activity for ROC in single-agent or in combination with cytotoxic agents. We have conducted a preliminary study to investigate effects of combination of bevacizumab and PLD for heavily pretreated patients with ROC. METHODS: Thirty patients with ROC were treated with combination therapy with weekly bevacizumab and PLD, 2 mg/kg of continuous weekly bevacizumab and 10 mg/m(2) of PLD (3 weeks on, 1 week off). The treatment was continued until development of disease progression, or unmanageable adverse effects. Response evaluation was based upon Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0, and Gynecologic Cancer Intergroup (GCIG) CA125 response criteria. Adverse effects were analyzed according to Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. RESULTS: Overall response rate was 33%, and clinical benefit rate (CR+PD+SD) was 73%. Median progression-free survival was 6 months (range: 2-20 months), and a 6-months progression-free survival was 47%. Any hematological toxicities more than grade 3 were not observed. Two cases developed non-hematologic toxicities more than grade 2; a case with grade 3 hand-foot syndrome, another with grade 3 gastrointestinal perforation (GIP). The case with GIP was conservatively treated and recovered after 2 months, and there was no case with treatment-related death. CONCLUSION: The present investigation suggested that combination therapy with bevacizumab and PLD was active and well tolerated for patients with ROC. We recommend the regimen be evaluated in further clinical studies.